Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 55.75
+0.80 (1.46%)
Sep 29, 2025, 4:08 PM HKT
Everest Medicines Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Net Income | -658.75 | -1,041 | -844.46 | -247.28 | -1,009 | -5,658 | Upgrade |
Depreciation & Amortization | 151.94 | 128.62 | 72.75 | 40.23 | 30.76 | 20.4 | Upgrade |
Other Amortization | 5 | 5 | 4.03 | 2.55 | 0.37 | 10.05 | Upgrade |
Loss (Gain) From Sale of Assets | 0.03 | - | 1.43 | -1,320 | - | - | Upgrade |
Asset Writedown & Restructuring Costs | - | 356.34 | 51.97 | 16.49 | - | - | Upgrade |
Loss (Gain) From Sale of Investments | 0.01 | 0.01 | -0.85 | 21.75 | - | - | Upgrade |
Stock-Based Compensation | 103.32 | 91.1 | 73.42 | 206.5 | 224.98 | 117.27 | Upgrade |
Provision & Write-off of Bad Debts | 0.17 | 0.22 | - | - | - | - | Upgrade |
Other Operating Activities | -53.55 | -48.35 | -46.19 | 153.15 | -11.67 | 4,963 | Upgrade |
Change in Accounts Receivable | -41.68 | -313.93 | -44.64 | -5.17 | -0.05 | - | Upgrade |
Change in Inventory | 17.03 | 2.86 | -7.31 | -11.19 | -0.45 | - | Upgrade |
Change in Accounts Payable | 66.23 | 106.69 | -116.55 | 70.43 | 73.97 | 86.68 | Upgrade |
Change in Other Net Operating Assets | -35.78 | 33.32 | 87.22 | -83.63 | -39.13 | -10.77 | Upgrade |
Operating Cash Flow | -446.04 | -679.51 | -769.19 | -1,156 | -729.94 | -471.9 | Upgrade |
Capital Expenditures | -41.64 | -65.41 | -117.34 | -355.92 | -109.95 | -8.6 | Upgrade |
Sale of Property, Plant & Equipment | - | - | 0.06 | 0.31 | - | - | Upgrade |
Sale (Purchase) of Intangibles | -126.55 | -138.75 | 1,432 | 488.17 | -865.87 | -511.33 | Upgrade |
Investment in Securities | 1,083 | 1,179 | -568.77 | -1,161 | - | - | Upgrade |
Other Investing Activities | 35.63 | - | 6.57 | - | - | - | Upgrade |
Investing Cash Flow | 950.4 | 974.4 | 752.5 | -1,028 | -975.82 | -519.93 | Upgrade |
Long-Term Debt Issued | - | 70 | 451.46 | - | - | 348.59 | Upgrade |
Total Debt Issued | 635.52 | 70 | 451.46 | - | - | 348.59 | Upgrade |
Long-Term Debt Repaid | - | -43.08 | -463.2 | -30.59 | -23.66 | -19.46 | Upgrade |
Net Debt Issued (Repaid) | 155.93 | 26.92 | -11.74 | -30.59 | -23.66 | 329.13 | Upgrade |
Issuance of Common Stock | 58.13 | 30.56 | 29.79 | 5.28 | 5.86 | 3,387 | Upgrade |
Repurchase of Common Stock | - | - | - | - | -58.71 | - | Upgrade |
Other Financing Activities | -20.25 | -19.68 | -7.95 | - | - | -10.05 | Upgrade |
Financing Cash Flow | 193.81 | 37.8 | 10.1 | -25.31 | -76.51 | 5,638 | Upgrade |
Foreign Exchange Rate Adjustments | 12.83 | 28.72 | 38.87 | 59.83 | -58.81 | -270.99 | Upgrade |
Net Cash Flow | 710.99 | 361.41 | 32.28 | -2,149 | -1,841 | 4,375 | Upgrade |
Free Cash Flow | -487.68 | -744.92 | -886.53 | -1,512 | -839.89 | -480.5 | Upgrade |
Free Cash Flow Margin | -57.29% | -105.41% | -703.97% | -11817.36% | -1555344.44% | - | Upgrade |
Free Cash Flow Per Share | -1.51 | -2.32 | -2.83 | -5.08 | -2.86 | -5.63 | Upgrade |
Cash Interest Paid | 20.25 | 19.68 | 7.95 | - | - | - | Upgrade |
Levered Free Cash Flow | - | -689.6 | 2,356 | -2,031 | -1,339 | -857.73 | Upgrade |
Unlevered Free Cash Flow | - | -675.73 | 2,371 | -2,028 | -1,336 | -836.57 | Upgrade |
Change in Working Capital | 5.8 | -171.07 | -81.28 | -29.56 | 34.35 | 75.91 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.